Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2020

View Archived Issues

CTA cleared in China to initiate phase IIa study of infigratinib in gastric cancer

Enrollment ongoing in phase III study of marzeptacog alfa

Amgen initiates phase III study of ABP-654 in moderate to severe plaque psoriasis

Braeburn receives complete response letter for Brixadi in the U.S.

First patient dosed in phase III ASPEN study of brensocatib in bronchiectasis

Cel-Sci reports preclinical data on LEAPS COV-19 peptides

Arcutis presents data from long-term safety study of ARQ-151 in plaque psoriasis

Biotest presents compositions comprising recombinant factor VIII protein

EPA/DHA does not show benefit in patients with cardiovascular risk

Royal Melbourne Institute of Technology describes new gold complexes

Bacainn completes first-in-human study BT-051

New inhibitors of autophagy identified at Deciphera Pharmaceuticals

New THR-beta agonists identified at Aligos Therapeutics

Bristol Myers Squibb patents TLR7/TLR8/TLR9 antagonists

Environmental support helps blood stem cells cope

Genethon cleared to begin clinical trial in France with GNT-0004 for Duchenne muscular dystrophy

OncoMyx presents armed Myxoma virus as potentially promising new oncolytic virotherapy

Appili initiates new phase III trial of Avigan for treatment of COVID-19

Phase III ATLANTIS results with Zepzelca and doxorubicin for SCLC

Tc24-C4.10E shows promise for the treatment of Chagas disease

CARB-X awards funding to German institutions

Galapagos begins phase II trial of CFTR inhibitor GLPG-2737 for ADPKD

reMYND initiates first-in-human trial of ReS19-T for Alzheimer's

New phase II trial evaluates LYT-100 for long COVID respiratory complications and related sequelae

FDA approves [68]Ga-PSMA-11 for PET imaging of PSMA-positive lesions in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...